Protalix BioTherapeutics Inc (PLX) - Financial and Strategic SWOT Analysis Review

  • ID: 4278518
  • SWOT Analysis
  • 44 pages
  • GlobalData
  • Protalix Biotherapeutics
1 of 5

FEATURED COMPANIES

  • Amicus Therapeutics Inc
  • Can-Fite BioPharma Ltd
  • Genentech Inc
  • Genzyme Corp
  • Shire LLC
  • MORE
Protalix BioTherapeutics Inc (PLX) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by the Author to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the potential opportunities and threats. The profile helps you formulate strategies that augment your business by enabling you to understand your partners, customers and competitors better.

The profile contains critical company information including:
  • Business description – A detailed description of the company’s operations and business divisions.
  • Corporate strategy – Analyst’s summarization of the company’s business strategy.
  • SWOT Analysis – A detailed analysis of the company’s strengths, weakness, opportunities and threats.
  • Company history – Progression of key events associated with the company.
  • Major products and services – A list of major products, services and brands of the company.
  • Key competitors – A list of key competitors to the company.
  • Key employees – A list of the key executives of the company.
  • Executive biographies – A brief summary of the executives’ employment history.
  • Key operational heads – A list of personnel heading key departments/functions.
  • Important locations and subsidiaries – A list and contact details of key locations and subsidiaries of the company.
  • Key manufacturing facilities – A list of key manufacturing facilities of the company.
  • Detailed financial ratios for the past five years – The latest financial ratios derived from the annual financial statements published by the company with 5 years history.
  • Interim ratios for the last five interim periods – The latest financial ratios derived from the quarterly/semi-annual financial statements published by the company for 5 interims history.
Highlights

Protalix BioTherapeutics Inc (Protalix) is a biopharmaceutical company that develops and commercializes recombinant therapeutic proteins. The company’s marketed product, Taliglucerase (taliglucerase alfa) is an enzyme replacement therapy (ERT) for the long-term treatment of adult patients with a confirmed diagnosis of type 1 Gaucher disease. The company also has pipeline product candidates that are intended for the treatment of Fabry disease; cystic fibrosis and gaucher disease. Protalix develops its proprietary pipeline of recombinant therapeutic proteins through its proprietary technology: ProCellEx System. Protalix is headquartered in Carmiel, Israel

Protalix BioTherapeutics Inc Key Recent Developments

Sep 21, 2018: Protalix BioTherapeutics Reports Positive Preliminary Data from the BRIDGE Study of pegunigalsidase alfa for the Treatment of Fabry Disease
Aug 13, 2018: Protalix Biotherapeutics names David Granot as board director
Aug 09, 2018: Protalix BioTherapeutics reports 2018 second quarter results and provides corporate update
May 09, 2018: Protalix BioTherapeutics Reports 2018 First Quarter Results and Provides Corporate Update
Mar 06, 2018: Protalix BioTherapeutics Reports 2017 Full Year Results and Provides Corporate Update

Key benefits of buying this profile include:

You get detailed information about the company and its operations to identify potential customers and suppliers.
  • The profile analyzes the company’s business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.
Understand and respond to your competitors’ business structure and strategies, and capitalize on their weaknesses. Stay up to date on the major developments affecting the company.
  • The company’s core strengths and weaknesses and areas of development or decline are analyzed and presented in the profile objectively. Recent developments in the company covered in the profile help you track important events.
Equip yourself with information that enables you to sharpen your strategies and transform your operations profitably.
  • Opportunities that the company can explore and exploit are sized up and its growth potential assessed in the profile. Competitive and/or technological threats are highlighted.
Scout for potential investments and acquisition targets, with detailed insight into the companies’ strategic, financial and operational performance.
  • Financial ratio presented for major public companies in the profile include the revenue trends, profitability, growth, margins and returns, liquidity and leverage, financial position and efficiency ratios.
Gain key insights into the company for academic or business research.
  • Key elements such as SWOT analysis, corporate strategy and financial ratios and charts are incorporated in the profile to assist your academic or business research needs.
Note: Some sections may be missing if data is unavailable for the company
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Amicus Therapeutics Inc
  • Can-Fite BioPharma Ltd
  • Genentech Inc
  • Genzyme Corp
  • Shire LLC
  • MORE
Section 1 - About the Company

Protalix BioTherapeutics Inc - Key Facts
Protalix BioTherapeutics Inc - Key Employees
Protalix BioTherapeutics Inc - Key Employee Biographies
Protalix BioTherapeutics Inc - Major Products and Services
Protalix BioTherapeutics Inc - History
Protalix BioTherapeutics Inc - Company Statement
Protalix BioTherapeutics Inc - Locations And Subsidiaries
Head Office
Other Locations & Subsidiaries

Section 2 – Company Analysis

Company Overview

Protalix BioTherapeutics Inc - Business Description
R&D Overview
Protalix BioTherapeutics Inc - Corporate Strategy
Protalix BioTherapeutics Inc - SWOT Analysis
SWOT Analysis - Overview
Protalix BioTherapeutics Inc - Strengths
Protalix BioTherapeutics Inc - Weaknesses
Protalix BioTherapeutics Inc - Opportunities
Protalix BioTherapeutics Inc - Threats
Protalix BioTherapeutics Inc - Key Competitors

Section 3 – Company Financial Ratios

Financial Ratios - Capital Market Ratios
Financial Ratios - Annual Ratios
Performance Chart
Financial Performance
Financial Ratios - Interim Ratios
Financial Ratios - Ratio Charts
Section 4 – Company’s Lifesciences Financial Deals and Alliances
Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Protalix BioTherapeutics Inc, Recent Deals Summary

Section 5 – Company’s Recent Developments

Aug 09, 2018: Protalix BioTherapeutics reports 2018 second quarter results and provides corporate update
May 09, 2018: Protalix BioTherapeutics Reports 2018 First Quarter Results and Provides Corporate Update
Mar 06, 2018: Protalix BioTherapeutics Reports 2017 Full Year Results and Provides Corporate Update
Nov 08, 2017: Protalix BioTherapeutics Reports 2017 Third Quarter Results and Provides Corporate Update
Aug 09, 2017: Protalix BioTherapeutics Reports 2017 Second Quarter Results and Provides Corporate Update
May 10, 2017: Protalix BioTherapeutics Reports 2017 First Quarter Results and Provides Corporate Update
Mar 16, 2017: Protalix BioTherapeutics Reports 2016 Full Year Results and Provides Corporate Update
Jan 09, 2017: Protalix BioTherapeutics Provides Review of 2016 and Strategic Outlook for 2017

Section 6 – Appendixs

Methodology
Ratio Definitions
About
Contact Us
Disclaimer

List of Tables

Protalix BioTherapeutics Inc, Key Facts
Protalix BioTherapeutics Inc, Key Employees
Protalix BioTherapeutics Inc, Key Employee Biographies
Protalix BioTherapeutics Inc, Major Products and Services
Protalix BioTherapeutics Inc, History
Protalix BioTherapeutics Inc, Subsidiaries
Protalix BioTherapeutics Inc, Key Competitors
Protalix BioTherapeutics Inc, Ratios based on current share price
Protalix BioTherapeutics Inc, Annual Ratios
Protalix BioTherapeutics Inc, Annual Ratios (Cont...1)
Protalix BioTherapeutics Inc, Annual Ratios (Cont...2)
Protalix BioTherapeutics Inc, Interim Ratios
Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Type, 2012 to YTD 2018
Protalix BioTherapeutics Inc, Recent Deals Summary
Currency Codes
Capital Market Ratios
Equity Ratios
Profitability Ratios
Cost Ratios
Liquidity Ratios
Leverage Ratios
Efficiency Ratios

List of Figures

Protalix BioTherapeutics Inc, Performance Chart (2013 - 2017)
Protalix BioTherapeutics Inc, Ratio Charts
Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018
Protalix BioTherapeutics Inc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • Shire LLC
  • Genzyme Corp
  • Genentech Inc
  • Can-Fite BioPharma Ltd
  • BiondVax Pharmaceuticals Ltd
  • Amicus Therapeutics Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll